Raban Jeger

Has grant

University Hospital Basel
Country flagSwitzerland

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

BAsel Stent Kosten Effektivitäts Trial - Drug Eluting Balloons vs. Drug Eluting Stents in Small Vessel Interventions (BASKET-SMALL 2)

Open Date: 2012-04-01

Close Date: 2017-12-31

Grant: Close

BAsel Stent Kosten Effektivitäts Trial - SAphenous Venous graft Angioplasty using Glycoprotein IIb/IIIa receptor inhibitors and drug-Eluting stents

Open Date: 2008-04-01

Close Date: 2010-03-31

Articles (21)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Background In view of the rising global burden of severe symptomatic aortic stenosis, its early recognition and treatment is key. Although patients with classical low‐flow, low‐gradient (C‐LFLG) aortic stenosis have higher rates of death after transcatheter aortic valve implantation (TAVI) when compared with patients with high‐gradient (HG) aortic stenosis, there is conflicting evidence on the death rate in patients with severe paradoxical low‐flow, low‐gradient (P‐LFLG) aortic stenosis. Therefore, we aimed to compare outcomes in real‐world patients with severe HG, C‐LFLG, and P‐LFLG aortic stenosis undergoing TAVI. Methods and Results Clinical outcomes up to 5 years were addressed in the 3 groups of patients enrolled in the prospective, national, multicenter SwissTAVI registry. A total of 8914 patients undergoing TAVI at 15 heart valve centers in Switzerland were analyzed for the purpose of this study. We observed a significant difference in time to death at 1 year after TAVI, with the lowest observed in HG (8.8%) aortic stenosis, followed by P‐LFLG (11.5%; hazard ratio [HR], 1.35 [95% CI, 1.16–1.56]; P <0.001) and C‐LFLG (19.8%; HR, 1.93 [95% CI, 1.64–2.26]; P <0.001) aortic stenosis. Cardiovascular death showed similar differences between the groups. At 5 years, the all‐cause death rate was 44.4% in HG, 52.1% in P‐LFLG (HR, 1.35 [95% CI, 1.23–1.48]; P <0.001), and 62.8% in C‐LFLG aortic stenosis (HR, 1.7 [95% CI, 1.54–1.88]; P <0.001). Conclusions Up to 5 years after TAVI, patients with P‐LFLG have higher death rates than patients with HG aortic stenosis but lower death rates than patients with C‐LFLG aortic stenosis.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (9)

Nikki Rommers

Vrije Universiteit Brussel

BELGIUM
View details

Omer Dzemali

Director, Prof. Dr. Dr. h.c.

University of Zurich

SWITZERLAND
View details

Michael Osthoff

University Hospital Basel

SWITZERLAND
View details

Soledad Ojeda Pineda

Profesora Asociada Cis Con Doctorado

Universidad de Córdoba

SPAIN
View details

Raphael Twerenbold

Professor (W3) of clinical cardiology (focus on biomarkers and genomics)

University Heart and Vascular Center Hamburg

GERMANY
View details

Olivier Muller

Chair & full professor

Centre Hospitalier Universitaire Vaudois

SWITZERLAND
View details

Oliver Reuthebuch

University Hospital Basel

SWITZERLAND
View details

Mark Spence

Royal College of Surgeons in Ireland

IRELAND
View details

Marten Trendelenburg

-

SWITZERLAND
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.